Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609317 | 1.00 | PRSS1 (0.43) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL12228407 | 0.95 | PRSS1 (0.43) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL12228402 | 0.95 | PRSS1 (0.43) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL9609298 | 0.93 | LMNA (0.51) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL17917569 | 0.92 | PRSS1 (0.50) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL9608407 | 0.92 | PRSS1 (0.50) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL9608418 | 0.92 | PRSS1 (0.50) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL9609339 | 0.91 | MAPT (0.38) | PRSS1PRSS2PRSS3LMNAHSD17B10 | |
| SCHEMBL9609304 | 0.90 | MEN1 (0.38) | LMNAHSD17B10MEN1MAPTKMT2A | |
| SCHEMBL9608477 | 0.89 | PRSS1 (0.44) | PRSS1PRSS2PRSS3LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957140-B2 | Triazine derivative, ultraviolet absorber, and resin composition | FUJIFILM CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8748520-B2 | Polycarbonate resin composition containing triazine compound and molded article using the same | FUJIFILM CORPORATION (JP) | 2014-06-10 | — | — | US | disclosed |
| US-8623990-B2 | Polyester resin composition | FUJIFILM CORPORATION (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120301696-A1 | POLYESTER RESIN COMPOSITION | FUJIFILM CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120136098-A1 | NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION | FUJIFILM CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110077331-A1 | POLYCARBONATE RESIN COMPOSITION CONTAINING TRIAZINE COMPOUND AND MOLDED ARTICLE USING THE SAME | FUJIFILM CORPORATION (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136098-A1 | NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION | C1R, RPSA, H1-2 | PRSS1 2006/4885PRSS2 2119/4885PRSS3 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.